标题
The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 17, Issue 1, Pages 73-87
出版商
Informa UK Limited
发表日期
2017-10-20
DOI
10.1080/14740338.2018.1390562
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
- (2017) Teresa Amaral et al. EUROPEAN JOURNAL OF CANCER
- Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
- (2017) Adil Daud et al. Journal of Hematology & Oncology
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
- (2016) Christopher J. Anker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Learning from and engaging patients/families during the implementation of a new medical record system.
- (2016) Stephen Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms
- (2016) Diptee Kulkarni et al. PHARMACOGENOMICS
- Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
- (2016) Andrew J. Dooley et al. Targeted Oncology
- Radiosensitization by BRAF inhibitor therapy--mechanism and frequency of toxicity in melanoma patients
- (2015) M. Hecht et al. ANNALS OF ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
- (2015) Ilaria Penna et al. Oncotarget
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
- (2015) Giuliana Carlos et al. JAMA Dermatology
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
- (2014) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy
- (2014) James J. Harding et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
- (2013) Giusy Gentilcore et al. BMC CANCER
- Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
- (2013) A. Koop et al. BRITISH JOURNAL OF DERMATOLOGY
- Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
- (2013) Imke Satzger et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity
- (2013) Natalia Rompoti et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma
- (2013) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
- (2013) Geoffrey T. Gibney et al. Nature Reviews Clinical Oncology
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- Paradoxical oncogenesis: are all BRAF inhibitors equal?
- (2013) Alexander M. Menzies et al. Pigment Cell & Melanoma Research
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management
- (2012) Lisa Zimmer ARCHIVES OF DERMATOLOGY
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
- (2012) Emily Y. Chu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Cutaneous toxicities of RAF inhibitors
- (2012) Rachael Anforth et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials
- (2012) Christine M. Lovly et al. PLoS One
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
- (2010) Hui Cheng et al. CIRCULATION RESEARCH
- Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
- (2010) K. Schad et al. CLINICAL CANCER RESEARCH
- Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
- (2010) Yevgeniy Balagula et al. INVESTIGATIONAL NEW DRUGS
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started